Delivery Order SPE2DB22D1017-SPE2DB25FG8UT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,785.70 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) under a firm fixed price contract. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. This delivery order represents a non-competitive purchase executed under an existing contract vehicle and will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract valued at $43,076.07. This non-set-aside competitive award was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count packages) valued at $3,152.98 under a firm fixed-price contract. The award was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside delivery order will be fulfilled at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is the prime...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $27,320.78. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count units) valued at $2,366.72, with a completion date of July 25, 2025. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation, issued to fulfill pharmaceutical supply requirements for federal military and healthcare systems. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $7,869.72 delivery order to AmerisourceBergen Drug Corp for 60-count tablets of Otezla 30 mg, a pharmaceutical product for treating autoimmune conditions. This competitive award, issued on July 22, 2025, represents a firm fixed-price contract with a completion date of July 23, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla (apremilast) 30 mg tablets in a quantity of 60 units, valued at $1,311.62. This competitively awarded, firm fixed-price delivery order, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. The contract contains no set-aside designation and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $5.25K. The award, issued on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a competitively awarded, non-set-aside transaction. Performance will be conducted at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $12,258.25 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg, with an ultimate completion date of July 31, 2025. This is a firm fixed price, non-set-aside contract with performance at the vendor's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling...
- The Defense Logistics Agency awarded a $13,321.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count packages) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside competitive award issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The pharmaceutical distributor, headquartered in...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG8UTDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) under a firm fixed-price contract valued at $2,623.24. The award was issued on August 1, 2025, with an ultimate completion date of August 4, 2025, and represents a non-set-aside, competitively awarded transaction. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform delivery from its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The prime IDV functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The Otezla tablets—an oral immunosuppressant used primarily in dermatological and rheumatological treatments—fulfill routine pharmaceutical procurement needs within the Defense Health Agency's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 8/1/25 |